Bicara Therapeutics posts Q3 2026 results and advances FORTIFI-HN01 trial enrollment

Bicara Therapeutics posts Q3 2026 results and advances FORTIFI-HN01 trial enrollment
Bicara Q3 results and trial update

Bicara Therapeutics announced its financial results for the third quarter of 2026 and provided a business update on its operations.

The company reported substantial enrollment progress in the FORTIFI-HN01 pivotal trial for first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma. Bicara Therapeutics expects topline results from an interim analysis of this trial in mid-2027.

Earlier this year, Bicara Therapeutics initiated the FORTIFI-FLEX trial targeting HPV-negative head and neck cancer with a specific dosing regimen. The company had previously scheduled its third quarter financial results and business update for November 9, as outlined in a conference call announcement. These developments reflect continued progress in the firm’s clinical and corporate activities.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.